DOCSLIB.ORG

TABLE 1 Studies of Antagonist Activity in Constitutively Active

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
TABLE 1 Studies of Antagonist Activity in Constitutively Active TABLE 1 Studies of antagonist activity in constitutively active receptors systems shown to demonstrate inverse agonism for at least one ligand Targets are natural Gs and constitutively active mutants (CAM) of GPCRs. Of 380 antagonists, 85% of the ligands demonstrate inverse agonism. Receptor Neutral Antagonist Inverse Agonist Reference Human β2-adrenergic Dichloroisoproterenol, pindolol, labetolol, timolol, Chidiac et al., 1996; Azzi et alprenolol, propranolol, ICI 118,551, cyanopindolol al., 2001 Turkey erythrocyte β-adrenergic Propranolol, pindolol Gotze et al., 1994 Human β2-adrenergic (CAM) Propranolol Betaxolol, ICI 118,551, sotalol, timolol Samama et al., 1994; Stevens and Milligan, 1998 Human/guinea pig β1-adrenergic Atenolol, propranolol Mewes et al., 1993 Human β1-adrenergic Carvedilol CGP20712A, metoprolol, bisoprolol Engelhardt et al., 2001 Rat α2D-adrenergic Rauwolscine, yohimbine, WB 4101, idazoxan, Tian et al., 1994 phentolamine, Human α2A-adrenergic Napthazoline, Rauwolscine, idazoxan, altipamezole, levomedetomidine, Jansson et al., 1998; Pauwels MPV-2088 (–)RX811059, RX 831003 et al., 2002 Human α2C-adrenergic RX821002, yohimbine Cayla et al., 1999 Human α2D-adrenergic Prazosin McCune et al., 2000 Rat α2-adrenoceptor MK912 RX821002 Murrin et al., 2000 Porcine α2A adrenoceptor (CAM- Idazoxan Rauwolscine, yohimbine, RX821002, MK912, Wade et al., 2001 T373K) phentolamine Human α2A-adrenoceptor (CAM) Dexefaroxan, (+)RX811059, (–)RX811059, RS15385, yohimbine, Pauwels et al., 2000 atipamezole fluparoxan, WB 4101 Hamster α1B-adrenergic (CAM) Prazosin, WB 4101, phentolamine, REC15/3039, Rossier et al., 1999; Hein et REC15/2739, REC15/2869, REC15/3011, 5- al., 2001 methylurapidil, BMY 7378, WAY 100,635, S(+)- niguldipine, SNAP 5089, BE 2254, tamsulosin, RS- 17053, terazosin, (+)-cyclazosin, (–)-cyclazocine, REC15/2615, alfuzosin, indoramin, corynthanine, spiperone, AH11110A, doxazosin, SB 216,469 Rat α1d-adrenergic WB 4101 BMY 7378, phentolamine, chloroethylclonidine, 5- Garcia-Sainz and Torres- methyl-urapidil Padilla, 1999 Human α1A-adrenergic (CAM) REC15/3039, 5-methylurapidil, WAY 100,635, WB 4101, Rossier et al., 1999; Zhu et al., REC15/2739, S(+)niguldipine, SNAP 5089, phentolamine, BE2254, 2000 REC15/2869, tamsulosin, RS-17053, prazosin, terazosin, (+)cyclazosin, REC15/3011, KMD- (–)-cyclazocine, REC15/2615, alfuzosin indoramin 3213 corynthanin, spiperone, AH11110A, BMY 7378 Human α1B-adrenergic (CAM) Prazosin, WB 4101, phentolamine Cotecchia et al., 1995 Human histamine H1 Cetirizine, loratridine, epinastine, acrivastine, Bakker et al., 2000, 2001 mepyramine, KW 4679 Histamine H2 Burimamide Cimetidine, ranitidine Smit et al., 1996 Histamine H2 Tioditine Monczor et al., 1998 Human histamine H3 VUF4904 Iodophenpropit, thioperamide, clopenpropit, VUF4903, Morisset et al., 2000; Wieland VUF5202, ciproxifan, GT2394, JB98064 et al., 2001; Wulff et al., 2002 Rat histamine H3 Iodophenpropit, thioperamide, clopenpropit, ciproxifan Wulff et al., 2002 Human bradykinin B2 FR 173657 Drube and Liebmann, 2000 Rat bradykinin B2 HOE140, NPC17731, NPC567 Leeb-Lundberg et al., 1994 Rat 5-HT2C Spiroxatrine, BOL Spiperone ketanserin, clozapine, methysergide, Barker et al., 1994; Westphal metergoline, mesulergine, ritanersin, mianserin, and Sanders-Bush, 1994; cyproheptadine, deramciclane Labrecque et al., 1995; Hartman and Northup, 1996; Palvimaki et al., 1998 Human 5-HT1A p-MPPF, WAY 100,135 Spiperone, p-MPPI, WAY 100,635, methiothepin Barr and Manning, 1997; Newman-Tancredi et al., 1997a,b; Stanton and Beer, 1997; Cosi and Koek, 2000 322 Rat 5-HT2A Cys Lys Chlorpromazine, clozapine, haloperidol, loxapine, Egan et al., 1998a,b risperidone, spiperone, ketanserin 312 Rat 5-HT2C Ser Klys Haloperidol, Mianserin, mesulergine, methysergide, clozapine, Herrick-Davis et al., 1997, chlorpromazine, olanzapine, ziprasidone, risperidone, cyproheptadine, 1998, 2000 perphenazine ketanserin Human 5-HT1B SB 18127 SB 224289, SB 236057, methiothepin, olanzapine, Gaster et al., 1998; Cayla et clozapine, risperidone, ocaperidone, S16924, ORG-5222, al., 1999; Millan et al., 1999; ziprasidone Newman-Tancredi et al., 2000; Audinot et al., 2001 Guinea Pig 5-HT1B SB 224289, methiothepin, ritanserin Pauwels et al., 1998 Human 5-HT1B (CAM) GR 55562, methiothepin, ritanserin Pauwels, 1997; Pauwels et al., 1999 Human 5-HT1C SB 228357, SB 243213 Bromidge et al., 2000a,b Human 5-HT1D SB 18127 Ketanserin, methiothepin, ocaperidone, SB 224289, Pauwels, 1997; Pauwels et al., ritanserin, olanzapine, clozapine, risperidone, 1997; Brys et al., 2000; ocaperidone, S16924, ORG-5222, ziprasidone, Audinot et al., 2000, 2001 haloperidol, chlorpromazine Human 5-HT2C-INI Thioridazine, Sertindole, zotepine, ziprasidone, tiospirone, olanzapine, Herrick-Davis et al., 2000 mesoridazine clozapine, risperidone, fluperlapine, tenilapine, loxapine trifluoperazine, fluphenazine, spiperone, haloperidol, pimozide, thiothixene, chlorpromazine, perphenazine Murine 5-HT4(a) RS100235 SB 207266, GR 125487 Claeysen et al., 2000 Human 5-HT4C ML10375 Blondel et al., 1998 Human 5-HT7 long Risperidone, methiothepin, mesulergine, clozapine, Thomas et al., 1998; Audinot olanzapine, ketanserin, SB 258719 et al., 2001 Rat dopamine D1A Sch23390; (–)- (+)-Butaclamol, chlorpromazine, clozapine, Cai et al., 1999 Butaclamol fluphenazine, cis-flupenthixol, haloperidol Human dopamine D3 Nafatotride Haloperidol, (+)-UH-232, (+)-AJ-76, raclopride, Griffon et al. 1996; Malmberg clozapine, fluphenazine, thioperazine, eticlopride, et al., 1998 prochlorperazine, risperidone, flupenthixol, pimozide, chlorpromazine, sulpiride Human dopamine D2 Haloperidol, flupenthixol Nilsson et al., 1996 Murine µ-opioid β-Flunaltrexamine Liu et al., 2001 Murine δ-opioid TIPP[ψ], TIPP, ICI 174864, RTI-5989, RTI-5989-23, RTI-5989-25 Costa and Herz, 1989; naloxone, MR2266, Mullaney et al., 1996; naltriben Szekeres and Traynor, 1997; benzylidenenaltrexone Zaki et al., 2001 Human δ-opioid H-Dmt-Tic-NH2, H-Dmt-Tic-OH, N,N(CH3)2Dmt-Tic-NH2, Tic-OH, HS Hoshohata et al., 1999; naltrindole, TIPP 378, (2S,3R)TMT-L-Tic-OH, ICI 174864, TICP(ψ) LaBarre et al., 2000 Rat µ-opioid D3,49(164) mutant Diprenorphine Naloxone, naltrexone, naloxone methiodide Li et al., 2001 Bovine adenosine A1 0861, WRC-0342 XAC, CPX, WRC-0571 Freissmuth et al., 1991 Human adenosine A1 N-0861, N-0840, WRC- CPX, XAC, CGS-15943, WRC-0571 Shryock et al., 1998 0342 NPY-1 BIBP3226 Vanderheyden et al., 1997 Human neurotensin 2 Neurotensin Levobastine, JMV431, JMV457, JMV509, JMV2004 Richard et al., 2001 Human calcitonin type 2 AC512, AC66, AC423 Chen et al., 1997, 1999a,b Rat calcitonin C1b AC512, SDZ-212-769, sCT-(8-32), SDZ-219-379 Pozvek et al., 1997 11 12 Human PTH (CAM) [Leu ,D-Trp ]hPTHrP(7-37)NH2T,; [D- Gardella et al., 1996 12 34 Trp ,Tyr ]bPTHrP(7-37)NH2T Kaposi’s sarcoma-associated IP-10 Geras-Raaka et al., 1998 Herpesvirus GPCR CCK L-740,093R Beinborn et al., 1998 Melanocortin-4 SHU9119 AgRP(83-132) Nijenhuis et al., 2001 Rat CB1 SR 141716A, CP-272871 Meschler et al., 2000 Human Melatonin 1A Luzindole Roka et al., 1999 Human CB1 SR 141716A, AM630 Landsman et al., 1998; MacLennan et al., 1998; Shire et al., 1999 Human CB2 SR 144528, AM630, cannabinol MacLennan et al., 1998; Bouaboula et al., 1999; Portier et al., 1999; Ross et al., 1999; Shire et al., 1999 Human TRH (CAM) Chlorodiazepoxide Grimberg et al., 1999 ORF-74 IP-10, SDF-1α, Met-SDF-1α, vMIP-II Rosenkilde et al., 1999 Vasopressin V2 (CAM) SR-121463A, OPC-31260 Morin et al., 1998 Porcine ADH Chlorpropamide Durr et al., 2000 Human PAF (CAM L231R) WEB2086, alprazolam, CV3988, BN52021 Dupré et al., 2001 GLP-1 Exendin-(9-39) Serre et al., 1998 Human MT1 melatonin N-[(1-H-Indol-2- N-[(1-H-Indol-2-yl) alkyl]acylamino deriv.5b,c,k Spadoni et al., 1998 yl)alkyl]acylamino deriv.8-11 Human metabotropic glutamate MPEP, BAY36-7620 Pagano et al., 2000; Carroll et receptor al., 2001 Human muscarinic m1 Atropine, pirenzepine, NMS, QNB, trihexylphenidyl, 4- Burstein et al., 1997 diphenylacetoxy-N-methylperidine Human muscarinic m3 Atropine, pirenzepine, NMS, QNB, trihexylphenidyl, 4- Burstein et al., 1997 diphenylacetoxy-N-methylperidine Human muscarinic m5 Atropine, pirenzepine, NMS, QNB, trihexylphenidyl, 4- Burstein et al., 1997 diphenylacetoxy-N-methylperidine Human muscarinic m2 Atropine, N-methylscopolamine, QNB, AF-DX 116 Jakubic et al., 1995 Human muscarinic m4 Atropine, N-methylscopolamine, QNB, AF-DX 116 Jakubic et al., 1995 Rat muscarinic Atropine, N-methylscopolamine, QNB, AF-DX 116 Jakubic et al., 1995 Human formyl peptide receptor N-t-butoxycarbonyl-[L- Cyclosporin Wenzel-Seifert et al., 1998 leucyl-phenala]2 (+)-AJ-76, (+)-(1S,2R)-5-methoxy-1-methyl-2-(propylamino)tetralin (+)-UH-232, (+)-(1S,2R)-5-methoxy-1-methyl-2-(dipropylamino)tetralin) (2S,3R)TMT-L-Tic-OH, β-methyl-2′,6′-dimethyltyrosine-L-tetrahydroquinoline-3-carboxylic acid AF-DX 116, 11-[[2-[(diethyl-amino)-methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one AgRP(83-132), Agouti-related protein (83-132) AH11110A, 1-(2-biphenyloxy)-4-imino-4-(1-piperidinyl)-2-butanol AM630, 6-iodopravadoline BAY36-7620, [(3aS,6aS)-6a-naphtalen-2-ylmethyl-5-methyliden-hexahydro-cyclopental[c]furan-1-on BE 2254, (2[-(4-hydroxyphenyl)-ethyl-aminomethyl]tetralone HCl BIBP3226, (R)-N2-(diphenylacetyl)-N-[(4-hydroxy-phenyl)methyl]-arginine amide BMY 7378, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4,5]decane-7,9-dione dihydrochloride BN52021, Ginkgolide B CGP20712A, [2-(3-carbamoyl-4-hydroxyphenoxy)-ethylamino]-3-[4-(1-methyl-4-trifluormethyl-2-imidazolyl)-phenoxy]-2-
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0224020 A1 Schoenhard (43) Pub
    US 2004O224020A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0224020 A1 Schoenhard (43) Pub. Date: Nov. 11, 2004 (54) ORAL DOSAGE FORMS WITH (22) Filed: Dec. 18, 2003 THERAPEUTICALLY ACTIVE AGENTS IN CONTROLLED RELEASE CORES AND Related U.S. Application Data IMMEDIATE RELEASE GELATIN CAPSULE COATS (60) Provisional application No. 60/434,839, filed on Dec. 18, 2002. (76) Inventor: Grant L. Schoenhard, San Carlos, CA (US) Publication Classification Correspondence Address: (51) Int. Cl. ................................................... A61K 9/24 Janet M. McNicholas (52) U.S. Cl. .............................................................. 424/471 McAndrews, Held & Malloy, Ltd. 34th Floor (57) ABSTRACT 500 W. Madison Street Chicago, IL 60661 (US) The present invention relates to oral dosage form with active agents in controlled release cores and in immediate release (21) Appl. No.: 10/742,672 gelatin capsule coats. Patent Application Publication Nov. 11, 2004 Sheet 1 of 3 US 2004/0224020 A1 r N 2.S Hr s Patent Application Publication Nov. 11, 2004 Sheet 2 of 3 US 2004/0224020 A1 r CN -8 e N va N . t Cd NOLLYRILNONOO Patent Application Publication Nov. 11, 2004 Sheet 3 of 3 US 2004/0224020 A1 US 2004/0224020 A1 Nov. 11, 2004 ORAL DOSAGE FORMS WITH released formulations, a long t is particularly disadvan THERAPEUTICALLY ACTIVE AGENTS IN tageous to patients Seeking urgent treatment and to maintain CONTROLLED RELEASE CORES AND MEC levels. A second difference in the pharmacokinetic IMMEDIATE RELEASE GELATIN CAPSULE profiles of controlled release in comparison to immediate COATS release drug formulations is that the duration of Sustained plasma levels is longer in the controlled release formula CROSS REFERENCED APPLICATIONS tions.
    [Show full text]
  • From Inverse Agonism to 'Paradoxical Pharmacology' Richard A
    International Congress Series 1249 (2003) 27-37 From inverse agonism to 'Paradoxical Pharmacology' Richard A. Bond*, Kenda L.J. Evans, Zsirzsanna Callaerts-Vegh Department of Pharmacological and Pharmaceutical Sciences, University of Houston, 521 Science and Research Bldg 2, 4800 Caltioun, Houston, TX 77204-5037, USA Received 16 April 2003; accepted 16 April 2003 Abstract The constitutive or spontaneous activity of G protein-coupled receptors (GPCRs) and compounds acting as inverse agonists is a recent but well-established phenomenon. Dozens of receptor subtypes for numerous neurotransmitters and hormones have been shown to posses this property. However, do to the apparently low percentage of receptors in the spontaneously active state, the physiologic relevance of these findings remains questionable. The possibility that the reciprocal nature of the effects of agonists and inverse agonists may extend to cellular signaling is discussed, and that this may account for the beneficial effects of certain p-adrenoceptor inverse agonists in the treatment of heart failure. © 2003 Elsevier Science B.V. All rights reserved. Keywords. Inverse agonism; GPCR; Paradoxical pharmacology 1. Brief history of inverse agonism at G protein-coupled receptors For approximately three-quarters of a century, ligands that interacted with G protein- coupled receptors (GPCRs) were classified either as agonists or antagonists. Receptors were thought to exist in a single quiescent state that could only induce cellular signaling upon agonist binding to the receptor to produce an activated state of the receptor. In this model, antagonists had no cellular signaling ability on their own, but did bind to the receptor and prevented agonists from being able to bind and activate the receptor.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0221245 A1 Kunin (43) Pub
    US 2010O221245A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0221245 A1 Kunin (43) Pub. Date: Sep. 2, 2010 (54) TOPICAL SKIN CARE COMPOSITION Publication Classification (51) Int. Cl. (76) Inventor: Audrey Kunin, Mission Hills, KS A 6LX 39/395 (2006.01) (US) A6II 3L/235 (2006.01) A638/16 (2006.01) Correspondence Address: (52) U.S. Cl. ......................... 424/133.1: 514/533: 514/12 HUSCH BLACKWELL SANDERS LLP (57) ABSTRACT 4801 Main Street, Suite 1000 - KANSAS CITY, MO 64112 (US) The present invention is directed to a topical skin care com position. The composition has the unique ability to treat acne without drying out the user's skin. In particular, the compo (21) Appl. No.: 12/395,251 sition includes a base, an antibacterial agent, at least one anti-inflammatory agent, and at least one antioxidant. The (22) Filed: Feb. 27, 2009 antibacterial agent may be benzoyl peroxide. US 2010/0221 245 A1 Sep. 2, 2010 TOPCAL SKIN CARE COMPOSITION stay of acne treatment since the 1950s. Skin irritation is the most common side effect of benzoyl peroxide and other anti BACKGROUND OF THE INVENTION biotic usage. Some treatments can be severe and can leave the 0001. The present invention generally relates to composi user's skin excessively dry. Excessive use of some acne prod tions and methods for producing topical skin care. Acne Vul ucts may cause redness, dryness of the face, and can actually garis, or acne, is a common skin disease that is prevalent in lead to more acne. Therefore, it would be beneficial to provide teenagers and young adults.
    [Show full text]
  • Ciproxifan, a Histamine H3 Receptor Antagonist, Reversibly Inhibits Monoamine Oxidase a and B Received: 05 September 2016 S
    www.nature.com/scientificreports OPEN Ciproxifan, a histamine H3 receptor antagonist, reversibly inhibits monoamine oxidase A and B Received: 05 September 2016 S. Hagenow1, A. Stasiak2, R. R. Ramsay3 & H. Stark1 Accepted: 07 December 2016 Ciproxifan is a well-investigated histamine H receptor (H3R) inverse agonist/antagonist, showing Published: 13 January 2017 3 an exclusively high species-specific affinity at rodent compared to human H3R. It is well studied as reference compound for H3R in rodent models for neurological diseases connected with neurotransmitter dysregulation, e.g. attention deficit hyperactivity disorder or Alzheimer’s disease. In a screening for potential monoamine oxidase A and B inhibition ciproxifan showed efficacy on both enzyme isoforms. Further characterization of ciproxifan revealed IC50 values in a micromolar concentration range for human and rat monoamine oxidases with slight preference for monoamine oxidase B in both species. The inhibition by ciproxifan was reversible for both human isoforms. Regarding inhibitory potency of ciproxifan on rat brain MAO, these findings should be considered, when using high doses in rat models for neurological diseases. As the H3R and monoamine oxidases are all capable of affecting neurotransmitter modulation in brain, we consider dual targeting ligands as interesting approach for treatment of neurological disorders. Since ciproxifan shows only moderate activity at human targets, further investigations in animals are not of primary interest. On the other hand, it may serve as starting point for the development of dual targeting ligands. Ciproxifan (cyclopropyl 4-(3-(1H-imidazol-4-yl)propyloxy)phenyl methanone) is a well characterized species-specific histamine 3H receptor (H3R) inverse agonist/antagonist (Fig.
    [Show full text]
  • Alpha^ and Beta^Blocking Agents: Pharmacology and Properties
    CURRENT DRUG THERAPY DONALD G. VIDT, MD AND ALAN BAKST, PharmD, EDITORS Alpha^ and beta^blocking agents: pharmacology and properties PROFESSOR B.N.C. PRICHARD • Adrenergic receptors have been separated into alpha and beta groups, which have then been further subdivided. Agents have been developed that block each type of receptor with varying degrees of specificity between the sub-types, leading to differences in pharmacodynamic profile. A more recent innovation has been the development of multiple action beta-blocking drugs, ie, those not only blocking the beta receptors but also posessing a peripheral vasodilator effect that may be due to alpha blockade, beta-2 stimulation, or a vasodilator action independent of either alpha or beta receptors. • INDEX TERMS: ALPHA BLOCKERS; BETA BLOCKERS; HYPERTENSION • CLEVE CLIN ] MED 1991; 58:33 7-350 HE CONCEPT that binding of Rosenblueth suggested that a transmitter released at catecholamines to receptors leads to differ- sympathetic nerve endings produced either inhibitory ing responses was first described by Langley, or excitatory responses as a result of combination with who in 1905 noted that a cell may make sympathin I or sympathin E at the receptor.3 Tmotor or inhibitory substances or both, and that "the The current classification of alpha and beta respon- effect of a nerve impulse depends upon the proportion ses is based on the classic work of Ahlquist,4 who of the two kinds of receptive substance which is af- studied six sympathomimetic amines and found two fected by the impulse."1 In 1906, Dale reported that patterns of reactivity. One group of actions, mediated ergot blocked the excitatory but not the inhibitory ac- by what were termed "alpha receptors," were principally tions of adrenaline.2 In 1933, Cannon and excitatory.
    [Show full text]
  • A,-, and P-Opioid Receptor Agonists on Excitatory Transmission in Lamina II Neurons of Adult Rat Spinal Cord
    The Journal of Neuroscience, August 1994, 74(E): 4965-4971 Inhibitory Actions of S,-, a,-, and p-Opioid Receptor Agonists on Excitatory Transmission in Lamina II Neurons of Adult Rat Spinal Cord Steven R. Glaum,’ Richard J. Miller,’ and Donna L. Hammond* Departments of lPharmacoloaical and Phvsioloqical Sciences and ‘Anesthesia and Critical Care, The University of Chicago, Chicago, Illinois 60637 . This study examined the electrophysiological consequences tor in rat spinal cord and indicate that activation of either of selective activation of 6,-, 6,-, or r-opioid receptors using 6,- or Qopioid receptors inhibits excitatory, glutamatergic whole-cell recordings made from visually identified lamina afferent transmission in the spinal cord. This effect may me- II neurons in thin transverse slices of young adult rat lumbar diate the ability of 6, or 6, receptor agonists to produce an- spinal cord. Excitatory postsynaptic currents (EPSCs) or po- tinociception when administered intrathecally in the rat. tentials (EPSPs) were evoked electrically at the ipsilateral [Key words: DPDPE, deltorphin, spinal cord slice, EPSP, dorsal root entry zone after blocking inhibitory inputs with 6-opioid receptor, DAMGO, naltriben, 7-benzylidene- bicuculline and strychnine, and NMDA receptors with o-2- naltrexone (BNTX), naloxone] amino+phosphonopentanoic acid. Bath application of the p receptor agonist [D-Ala2, KMePhe4, Gly5-ollenkephalin (DAMGO) or the 6, receptor agonist [D-Pen2, o-PerF]en- The dorsal horn of the spinal cord is an important site for the kephalin (DPDPE) produced a log-linear, concentration-de- production of antinociception by K- and 6-opioid receptor ag- pendent reduction in the amplitude of the evoked EPSP/ onists (Yaksh, 1993).
    [Show full text]
  • Evidence That Mcpp May Have Behavioural Effects Mediated by Central 5-Ht1c Receptors 1G.A
    Br. J. Pharmacol. (1988), 94, 137-147 Evidence that mCPP may have behavioural effects mediated by central 5-HT1c receptors 1G.A. Kennett & G. Curzon Department of Neurochemistry, Institute of Neurology, Queen Square, London WC1N 3BG 1 The effects of 1-(3-chlorophenyl)piperazine (mCPP) and 1-[3-(trifluoromethyl)phenyl] piperazine (TFMPP) on activity of rats in a novel cage, and on the rotorod and elevated bar co-ordination tests was examined. 2 Peripherally administered mCPP and TFMPP dose-dependently reduced locomotion, rearing, and feeding scores but not grooming of freely fed rats placed in a novel observation cage. Yawning behaviour was increased. Similar effects were also observed after injection of mCPP into the 3rd ventricle. 3 Co-ordination on a rotating drum of both untrained and trained rats was impaired following mCPP but co-ordination on an elevated bar was not. 4 The hypoactivity induced by mCPP was opposed by three antagonists with high affinity for the 5-hydroxytryptamine (5-HT1c) site; metergoline, mianserin, cyproheptadine and possibly also by a fourth antagonist mesulergine. Metergoline, mianserin and cyproheptadine also opposed the reduction in feeding scores. However, neither effect of mCPP was antagonized by the 5-HT2-receptor antagonists ketanserin or ritanserin, the 5-HT3-receptor antagonist ICS 205-930, the 5-HTlA and 5-HTIB-receptor antagonists (-)-pindolol, (-)-propranolol and (±)-cyanopindolol or the 5-HTIA-, 5-HT2- and dopamine receptor antagonist spiperone. The specific a2-adrenoceptor antagonist idazoxan was also without effect. 5 Hypoactivity induced by TFMPP was similarly antagonized by mianserin but unaffected by (±+-cyanopindolol. 6 These results suggest that the hypoactivity is mediated by central 5-HT1c-receptors and that mCPP and possibly TFMPP may be 5-HT1c-receptor agonists.
    [Show full text]
  • Subanesthetic Doses of Ketamine Transiently Decrease Serotonin Transporter Activity: a PET Study in Conscious Monkeys
    Neuropsychopharmacology (2013) 38, 2666–2674 & 2013 American College of Neuropsychopharmacology. All rights reserved 0893-133X/13 www.neuropsychopharmacology.org Subanesthetic Doses of Ketamine Transiently Decrease Serotonin Transporter Activity: A PET Study in Conscious Monkeys 1 1 1 1 1 Shigeyuki Yamamoto , Hiroyuki Ohba , Shingo Nishiyama , Norihiro Harada , Takeharu Kakiuchi , 1 ,2 Hideo Tsukada and Edward F Domino* 1 2 Central Research Laboratory, Hamamatsu Photonics KK, Hamakita, Japan; Department of Pharmacology, University of Michigan, Ann Arbor, MI, USA Subanesthetic doses of ketamine, an N-methyl-D-aspartic acid (NMDA) antagonist, have a rapid antidepressant effect which lasts for up to 2 weeks. However, the neurobiological mechanism regarding this effect remains unclear. In the present study, the effects of subanesthetic doses of ketamine on serotonergic systems in conscious monkey brain were investigated. Five young monkeys 11 underwent four positron emission tomography measurements with [ C]-3-amino-4-(2-dimethylaminomethyl-phenylsulfanyl)benzoni- 11 trile ([ C]DASB) for the serotonin transporter (SERT), during and after intravenous infusion of vehicle or ketamine hydrochloride in a 11 dose of 0.5 or 1.5 mg/kg for 40 min, and 24 h post infusion. Global reduction of [ C]DASB binding to SERT was observed during ketamine infusion in a dose-dependent manner, but not 24 h later. The effect of ketamine on the serotonin 1A receptor (5-HT1A-R) and dopamine transporter (DAT) was also investigated in the same subjects studied with [11C]DASB. No significant changes were observed in either 5-HT -R or DAT binding after ketamine infusion. Microdialysis analysis indicated that ketamine infusion transiently increased 1A serotonin levels in the extracellular fluid of the prefrontal cortex.
    [Show full text]
  • Zebrafish Behavioral Profiling Links Drugs to Biological Targets and Rest/Wake Regulation
    www.sciencemag.org/cgi/content/full/327/5963/348/DC1 Supporting Online Material for Zebrafish Behavioral Profiling Links Drugs to Biological Targets and Rest/Wake Regulation Jason Rihel,* David A. Prober, Anthony Arvanites, Kelvin Lam, Steven Zimmerman, Sumin Jang, Stephen J. Haggarty, David Kokel, Lee L. Rubin, Randall T. Peterson, Alexander F. Schier* *To whom correspondence should be addressed. E-mail: [email protected] (A.F.S.); [email protected] (J.R.) Published 15 January 2010, Science 327, 348 (2010) DOI: 10.1126/science.1183090 This PDF file includes: Materials and Methods SOM Text Figs. S1 to S18 Table S1 References Supporting Online Material Table of Contents Materials and Methods, pages 2-4 Supplemental Text 1-7, pages 5-10 Text 1. Psychotropic Drug Discovery, page 5 Text 2. Dose, pages 5-6 Text 3. Therapeutic Classes of Drugs Induce Correlated Behaviors, page 6 Text 4. Polypharmacology, pages 6-7 Text 5. Pharmacological Conservation, pages 7-9 Text 6. Non-overlapping Regulation of Rest/Wake States, page 9 Text 7. High Throughput Behavioral Screening in Practice, page 10 Supplemental Figure Legends, pages 11-14 Figure S1. Expanded hierarchical clustering analysis, pages 15-18 Figure S2. Hierarchical and k-means clustering yield similar cluster architectures, page 19 Figure S3. Expanded k-means clustergram, pages 20-23 Figure S4. Behavioral fingerprints are stable across a range of doses, page 24 Figure S5. Compounds that share biological targets have highly correlated behavioral fingerprints, page 25 Figure S6. Examples of compounds that share biological targets and/or structural similarity that give similar behavioral profiles, page 26 Figure S7.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Histamine Receptors
    Tocris Scientific Review Series Tocri-lu-2945 Histamine Receptors Iwan de Esch and Rob Leurs Introduction Leiden/Amsterdam Center for Drug Research (LACDR), Division Histamine is one of the aminergic neurotransmitters and plays of Medicinal Chemistry, Faculty of Sciences, Vrije Universiteit an important role in the regulation of several (patho)physiological Amsterdam, De Boelelaan 1083, 1081 HV, Amsterdam, The processes. In the mammalian brain histamine is synthesised in Netherlands restricted populations of neurons that are located in the tuberomammillary nucleus of the posterior hypothalamus.1 Dr. Iwan de Esch is an assistant professor and Prof. Rob Leurs is These neurons project diffusely to most cerebral areas and have full professor and head of the Division of Medicinal Chemistry of been implicated in several brain functions (e.g. sleep/ the Leiden/Amsterdam Center of Drug Research (LACDR), VU wakefulness, hormonal secretion, cardiovascular control, University Amsterdam, The Netherlands. Since the seventies, thermoregulation, food intake, and memory formation).2 In histamine receptor research has been one of the traditional peripheral tissues, histamine is stored in mast cells, eosinophils, themes of the division. Molecular understanding of ligand- basophils, enterochromaffin cells and probably also in some receptor interaction is obtained by combining pharmacology specific neurons. Mast cell histamine plays an important role in (signal transduction, proliferation), molecular biology, receptor the pathogenesis of various allergic conditions. After mast cell modelling and the synthesis and identification of new ligands. degranulation, release of histamine leads to various well-known symptoms of allergic conditions in the skin and the airway system. In 1937, Bovet and Staub discovered compounds that antagonise the effect of histamine on these allergic reactions.3 Ever since, there has been intense research devoted towards finding novel ligands with (anti-) histaminergic activity.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0105536A1 Lewyn-Briscoe Et Al
    US 2011 01 05536A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0105536A1 Lewyn-Briscoe et al. (43) Pub. Date: May 5, 2011 (54) DOSING REGIMENASSOCATED WITH Publication Classification LONG-ACTING INUECTABLE PALIPERDONE ESTERS (51) Int. Cl. A 6LX 3/59 (2006.01) (76) Inventors: Peter H. Lewyn-Briscoe, A6IP 25/18 (2006.01) Newtown, PA (US); Cristiana Gassmann-Mayer, Pennington, NJ (US); Srihari Gopal, Belle Meade, (52) U.S. Cl. ................................................... S14/259.41 NJ (US); David W. Hough, Wallingford, PA (US); Bart M.M. Remmerie, Gent (BE); Mahesh N. (57) ABSTRACT Samtani, Flemington, NJ (US) The present application provides a method for treating (21) Appl. No.: 12/916,910 patients in need of psychiatric treatment, wherein said patient (22) Filed: Nov. 1, 2010 misses a stabilized dose of a monthly maintenance regimen of paliperidone palmitate. The present application also provides Related U.S. Application Data a method for treating psychiatric patients in need of a Switch (60) Provisional application No. 61/256,696, filed on Oct. ing treatment to paliperidone palmitate in a Sustained release 30, 2009. formulation. Patent Application Publication May 5, 2011 Sheet 1 of 6 US 2011/O105536 A1 FIG. 1 First-Order PrOCeSS Cp V CL Central (2) Zero-Order PrOCeSS Patent Application Publication May 5, 2011 Sheet 2 of 6 US 2011/O105536 A1 FIG. 2 25mgeq 50mgeq m-100mde::::: Missed doSe On WK 4. Patient returns On WK5 Missed doSe On WK 4. Patient returns On WK 6 -8-4 O 4 8 12 16 2024 -8-4 O 4 8 12 1620 24 Missed doSe On WK 4.
    [Show full text]